$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
medicaldrugs
medicaldrugs
Comparative analysis of purchase prices and channels of ruxolitinib cream (Opzelura) in different regions
2026-02-01 22:25:32
Check Details
Possible side effects and safety measures of long-term use of Epclusa
2026-02-01 22:25:32
Check Details
Introduction to sunitinib (Sutent) imported original drug manufacturers and drug production background
2026-02-01 22:25:32
Check Details
How to deal with tazerestat (Daveco) drug resistance and clinical medication recommendations
2026-02-01 22:25:32
Check Details
Research analysis on the mechanism of action and clinical targets of ceritinib/ceritinib (Zanda)
2026-02-01 22:25:32
Check Details
Comprehensive Medication Guide and Clinical Application Reference of Bestivan (Viliru)
2026-02-01 22:25:32
Check Details
How to use Dabrafenib (Teferal)? What is the clinical effect?
2026-02-01 22:25:32
Check Details
The key to cancer treatment in the new era: Interpretation of the opportunities and clinical practice of pemetinib/pemetinib in the Chinese market
2026-02-01 22:25:32
Check Details
Why do I feel less pain after taking Etrasimod-Velsipity?
2026-02-01 22:25:32
Check Details
How effective is vemurafenib/zobovo in the treatment of bowel cancer patients?
2026-02-01 22:25:32
Check Details
Is Guanfacine available in the country and how to purchase it?
2026-02-01 22:25:32
Check Details
What are the functions and effects of Acotiamide?
2026-02-01 22:25:32
Check Details
1
2
...
2093
2094
2095
2096
2097
2098
2099
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
User Agreement
2
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
3
What is the most important information I should know about WELIREG?
4
How to take and store WELIREG
5
How to take TRUSELTIQ correctly
6
How to deal with LONSURF side effects (1)
7
How to deal with LONSURF side effects (2)
8
Cabozantinib (Cabometyx)-new indication approved
9
What should I pay attention to when using atezolizumab/Tecentriq?
10
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma
11
Rituximab combined with chemotherapy approved in the United States for pediatric patients with specific malignant tumors
12
Lenvatinib and pembrolizumab trial results in unresectable hepatocellular carcinoma